Literature DB >> 31388283

Rechallenging to Hydroxycarbamide Post Thalidomide Treatment and Response in a Non Transfusion-Dependent Patient, is it Possible?

Paolo Ricchi1, Silvia Costantini1, Anna Spasiano1, Patrizia Cinque1, Tiziana Di Matola2, Massimiliano Ammirabile1,3, Aldo Filosa1.   

Abstract

Entities:  

Year:  2019        PMID： 31388283      PMCID： PMC6646488          DOI： 10.1007/s12288-019-01093-x

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  7 in total

1.  Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up.

Authors:  Andrea Mancuso; Aurelio Maggio; Disma Renda; Rosalba Di Marzo; Paolo Rigano
Journal:  Br J Haematol       Date:  2006-04       Impact factor: 6.998

Review 2.  β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies.

Authors:  Stefano Rivella
Journal:  Haematologica       Date:  2015-04       Impact factor: 9.941

3.  Soluble form of transferrin receptor as a biomarker of overall morbidity in patients with non-transfusion-dependent thalassaemia: a cross-sectional study.

Authors:  Paolo Ricchi; Massimiliano Ammirabile; Silvia Costantini; Anna Spasiano; Tiziana Di Matola; Roberto Verna; Alessia Pepe; Patrizia Cinque; Caterina Saporito; Aldo Filosa; Leonilde Pagano
Journal:  Blood Transfus       Date:  2016-05-03       Impact factor: 3.443

4.  Stem cell factor (c-kit ligand) influences eosinophil recruitment and histamine levels in allergic airway inflammation.

Authors:  N W Lukacs; R M Strieter; P M Lincoln; E Brownell; D M Pullen; H J Schock; S W Chensue; D D Taub; S L Kunkel
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

5.  Soluble form of transferrin receptor-1 level is associated with the age at first diagnosis and the risk of therapeutic intervention and iron overloading in patients with non-transfusion-dependent thalassemia.

Authors:  Paolo Ricchi; Antonella Meloni; Silvia Costantini; Anna Spasiano; Tiziana Di Matola; Alessia Pepe; Patrizia Cinque; Aldo Filosa
Journal:  Ann Hematol       Date:  2017-07-14       Impact factor: 3.673

6.  The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study.

Authors:  Paolo Ricchi; Massimiliano Ammirabile; Silvia Costantini; Patrizia Cinque; Alfonso Galeota Lanza; Anna Spasiano; Tiziana Di Matola; Giovanni Di Costanzo; Leonilde Pagano; Luciano Prossomariti
Journal:  Expert Opin Drug Saf       Date:  2010-11       Impact factor: 4.250

7.  The long-term and extensive efficacy of low dose thalidomide in a case of an untransfusable patient with Non-Transfusion-Dependent Thalassemia.

Authors:  Paolo Ricchi; Silvia Costantini; Anna Spasiano; Gianfranco De Dominicis; Tiziana Di Matola; Patrizia Cinque; Massimiliano Ammirabile; Maria Marsella; Aldo Filosa
Journal:  Blood Cells Mol Dis       Date:  2016-01-16       Impact factor: 3.039
  7 in total
  1 in total

Review 1.  Investigating the Efficacy and Safety of Thalidomide for Treating Patients With ß-Thalassemia: A Meta-Analysis.

Authors:  Yanfei Lu; Zhenbin Wei; Gaohui Yang; Yongrong Lai; Rongrong Liu
Journal:  Front Pharmacol       Date:  2022-01-11       Impact factor: 5.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.